Difference between revisions of "Arsenic trioxide (Trisenox)"
Jump to navigation
Jump to search
(updated content) |
m (categories) |
||
Line 15: | Line 15: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
+ | |||
+ | [[Category:Drug index]] | ||
+ | [[Category:Chemotherapy]] | ||
+ | [[Category:Acute myeloid leukemia medications]] |
Revision as of 00:55, 8 October 2012
General information
Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Arsenic trioxide (Trisenox) patient drug information (Chemocare)[3]
- Arsenic trioxide (Trisenox) patient drug information (UpToDate)[4]